1,188 results
Showing 1–20 · 0.09 seconds · RSS
Blood Cancer Journal
Scopus
ISSN 2044-5385 · Nature Publishing Group · 1,188 articles in the index
-
Journal Article
Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies
Abstract Virus-associated hematological malignancies have become a key focus in oncology research due to their complex pathological mechanisms and unique immune escape capabilities. In recent years, research in this area has increased with a deeper understanding of the role of viruses in…
-
Journal Article
Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab
Abstract Patients with relapsed/refractory multiple myeloma (RRMM) who are treated with BCMA-directed bispecific antibodies (BsAbs) are at an increased risk for infections. Previous studies have shown that treatment with intravenous immunoglobulin (IVIG) reduced the risk for severe infections…
-
Journal Article
Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy
Abstract Genome-wide association studies (GWAS) have identified germline genetic variants for follicular lymphoma (FL) susceptibility. We conducted a GWAS of prognosis in FL patients to identify genetic predictors of event-free survival (EFS) as well as failure within the first 24 months after…
-
Journal Article
Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial
Abstract This clinical trial (NCT05347641) evaluated efficacy and safety of penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in patients with newly diagnosed (ND) primary central nervous system lymphoma (PCNSL). Patients received an induction treatment of six…
-
Journal Article
Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma
Abstract Long-term follow-up of the CASSIOPEIA trial (NCT02541383) demonstrated superior progression-free survival (PFS) with daratumumab, both in combination with bortezomib, thalidomide, and dexamethasone during induction and consolidation, and during maintenance therapy, in transplant-eligible…
-
Journal Article
Genomic loss of MLH1/PMS2 loci defines a mismatch repair deficient subgroup in monomorphic epitheliotropic intestinal T-cell lymphoma
Abstract Primary intestinal T-cell lymphomas (ITCLs), comprising enteropathy-associated T-cell lymphoma (EATL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), are rare aggressive tumors. The role of DNA mismatch repair (MMR) deficiency (dMMR) and microsatellite instability (MSI)…
-
Journal Article
Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies
Abstract Outcomes in B-cell acute lymphoblastic leukemia (ALL) have improved over time due to therapeutic advances, and improved disease monitoring and prognostication. The BCR::ABL1 tyrosine kinase inhibitors (TKIs) were the first targeted therapies to significantly impact the therapeutic…
-
Journal Article
Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study
Abstract Diffuse large B-cell lymphoma (DLBCL) remains clinically heterogeneous, and outcomes with R-CHOP are suboptimal in patients carrying high-risk genomic alterations such as MYD88, CD79B, NOTCH1, TP53 mutations or MYC rearrangements. Many of these lesions are associated with aberrant BCR…
-
Journal Article
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia
Abstract Inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate, has demonstrated high response rates and measurable residual disease (MRD)-negativity in acute lymphoblastic leukemia (ALL). This phase 2 single-center study evaluated inotuzumab 0.6 mg/m2 day 1 and 0.3 mg/m2 day 8 (cycle 1)…
-
Journal Article
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database
Abstract Monotherapy with hypomethylating agents (HMA) remains the standard of care for patients with higher-risk myelodysplastic neoplasms (HR-MDS). Recently, the randomized phase III VERONA study evaluating azacitidine plus venetoclax (VEN) versus azacitidine plus placebo in newly diagnosed…
-
Journal Article
Temporal trends and demographic patterns in multiple myeloma incidence in the United States: a 24-year analysis of the CDC WONDER database (1999–2022)
Abstract Multiple myeloma (MM) is a plasma cell malignancy associated with significant morbidity and mortality. Recent advances in the treatment modalities have improved survival, but less is known about MM incidence and associated demographic disparities across sex, age, and racial/ethnic groups…
-
Journal Article
Circulating CD20-positive extracellular vesicles impair rituximab efficacy and predict outcomes in diffuse large B-cell lymphoma
Abstract Rituximab, an anti-CD20 monoclonal antibody, is a cornerstone of therapy for diffuse large B-cell lymphoma (DLBCL), yet a substantial proportion of patients develop treatment failure. While loss of CD20 expression has been considered a major mechanism of resistance, additional mechanisms…
-
Journal Article
Toward more accurate adverse event attribution in multiple myeloma clinical trials
Abstract Adverse event (AE) attribution and reporting in multiple myeloma (MM) clinical trials rely on frameworks developed for cytotoxic chemotherapy that are poorly suited to the modern therapeutic landscape. This review identifies systematic limitations at every stage of AE reporting and…
Showing at most 50 pages. Narrow your search with filters for more specific results.